Randomized, double-blind phase 3 study evaluating neoadjuvant platinum-based chemotherapy with perioperative pembrolizumab or placebo in resectable stage IIB or IIIA NSCLC: KEYNOTE-671.

被引：17
|
作者：
Fernando, Hiran C.
Yang, Jing
Ferraro, Geri L.
Keller, Steven M.
机构：
[1] INOVA Fairfax Med Campus, Dept Surg, Falls Church, VA USA
[2] INOVA Fairfax Med Campus, Dept Thorac Surg, Falls Church, VA USA
[3] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS8583
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8583
引用
收藏
页数：2
相关论文
共 50 条
  • [31] KEYNOTE-826: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
    Shapira-Frommer, Ronnie
    Alexandre, Jerome
    Monk, Bradley
    Fehm, Tanja N.
    Colombo, Nicoletta
    Caceres, Maria V.
    Hasegawa, Kosei
    Dubot, Coraline
    Li, Jerry Jing
    Stein, Karen
    Keefe, Stephen Michael
    Tewari, Krishnansu Sujata
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2-breast cancer
    Cardoso, F.
    Bardia, A.
    Andre, F.
    Cescon, D. W.
    McArthur, H.
    Telli, M.
    Loi, S.
    Cortes, J.
    Schmid, P.
    Harbeck, N.
    Denkert, C.
    Jackisch, C.
    Jia, L.
    Tryfonidis, K.
    Karantza, V.
    CANCER RESEARCH, 2019, 79 (04)
  • [33] Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastrooesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
    Shitara, Kohei
    Rha, Sun Young
    Wyrwicz, Lucjan S.
    Oshima, Takashi
    Karaseva, Nina
    Osipov, Mikhail
    Yasui, Hisateru
    Yabusaki, Hiroshi
    Afanasyev, Sergey
    Park, Young-Kyu
    Al-Batran, Salah-Eddin
    Yoshikawa, Takaki
    Yanez, Patricio
    Di Bartolomeo, Maria
    Lonardi, Sara
    Tabernero, Josep
    Van Cutsem, Eric
    Janjigian, Yelena Y.
    Oh, Do-Youn
    Xu, Jianming
    Fang, Xiao
    Shih, Chie-Schin
    Bhagia, Pooja
    Bang, Yung-Jue
    LANCET ONCOLOGY, 2024, 25 (02): : 212 - 224
  • [34] A Randomized, Double-Blind, Phase 2 Study of Perioperative MK-4280A (Coformulation of Favezelimab and Pembrolizumab) vs Pembrolizumab in Patients with Resectable Cutaneous Squamous Cell Carcinoma (cSCC)
    Koyfman, S. A.
    Silk, A. W.
    Davar, D.
    Schadendorf, D.
    Clark, J. R.
    Ladwa, R.
    Lee, J.
    Suttner, L. H.
    Groisberg, R.
    Jin, F.
    Hanna, G. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E86 - E86
  • [35] Neoadjuvant tislelizumab or placebo plus platinum-based chemotherapy followed by adjuvant tislelizumab or placebo in patients with resectable non-small cell lung cancer (NSCLC): A phase III trial in progress
    Wang, C.
    Wang, R.
    Ma, Y.
    Liang, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S746 - S746
  • [36] ECHO-306/KEYNOTE-715: A phase 3 study of first-line epacadostat plus pembrolizumab with or without platinum-based chemotherapy vs pembrolizumab plus platinum-based chemotherapy plus placebo for metastatic non-small cell lung cancer (mNSCLC)
    Hui, Rina
    Munteanu, Mihaela
    Zhao, Yufan
    Luo, Yiwen
    Samkari, Ayman
    Garassino, Marina Chiara
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] A Double-Blind, Randomized, Placebo-Controlled Phase 3 Noninferiority Study of Darbepoetin Alfa for Anemia in Advanced NSCLC
    Nagarkar, R.
    Gascon, P.
    Smakal, M.
    Syrigos, K.
    Barrios, C.
    Cardenas Sanchez, J.
    Zhang, L.
    Tomita, D.
    Park, J.
    Brandao, C. De Oliveira
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S359 - S359
  • [38] Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC
    Hensing, Thomas A.
    Wang, Xiaofei
    Stinchcombe, Thomas E.
    Gao, Junheng
    V. Knopp, Michael
    Watson, Mark
    Dudek, Arkadiusz Z.
    Graziano, Stephen L.
    Patel, Jyoti D.
    Faller, Bryan A.
    Dragnev, Konstantin H.
    Kozono, David
    Faller, Bryan
    Vokes, Everett E.
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (08):
  • [39] The randomized, double-blind, placebo-controlled phase 3 trial KEYNOTE-975: Pembrolizumab vs placebo in patients with esophageal carcinoma receiving concurrent definitive chemoradiotherapy
    Moehler, M.
    Enzinger, P.
    Bennouna, J.
    Doi, T.
    Shen, L.
    Kato, K.
    Adenis, A.
    Mamon, H.
    Fu, X.
    Cho, B.
    Desai, A.
    Bhagia, P.
    Shih, C.
    Shah, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S100 - S100
  • [40] Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous non-small cell lung carcinoma (NSCLC): KEYNOTE-189.
    Hall, Richard Delmar
    Gadgeel, Shirish M.
    Garon, Edward B.
    Bria, Emilio
    Reck, Martin
    Vida, John
    Zhou, Honghong
    Raftopoulos, Harry
    Gandhi, Leena
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345